Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis

A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Allergen BioCube Study Evaluating the Efficacy and Safety of Nasapaque Nasal Solution in a Population of Adult Subjects With Seasonal Allergic Rhinitis

Single-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy and safety study using the Allergen BioCube (ABC).

Key Inclusion Criteria:

• Must be 18 years of age and provide written informed consent and sign the HIPAA form
• Must have history of allergic rhinitis
• Must have positive response to Allergen BioCube

Key Exclusion Criteria:

• Must not have a significant illness such as moderate to severe allergic asthmatic reactions
• Must not have compromised lung function
• Must not use any disallowed medications
• Must not have been in an investigational study in the last 30 days